Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.50 |
| ▸ | NOS1 | P29475 | 3/20 | 0.50 |
| ▸ | NOS2 | P35228 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.50 |
| ▸ | RGS12 | O14924 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188089 | 1.00 | NOS3 (0.50) | NOS3NOS1NOS2USP2PKM | |
| SCHEMBL21690071 | 1.00 | NOS3 (0.50) | NOS3NOS1NOS2USP2PKM | |
| SCHEMBL29430356 | 1.00 | NOS3 (0.50) | NOS3NOS1NOS2USP2PKM | |
| SCHEMBL6530512 | 0.86 | PTPN1 (0.48) | NOS3NOS1NOS2USP2PKM | |
| SCHEMBL29401250 | 0.86 | PKM (0.58) | NOS3NOS1NOS2USP2PKM | |
| SCHEMBL268942 | 0.86 | PKM (0.58) | NOS3NOS1NOS2USP2PKM | |
| SCHEMBL44126 | 0.86 | PKM (0.58) | NOS3NOS1NOS2USP2PKM | |
| SCHEMBL44127 | 0.86 | PKM (0.58) | NOS3NOS1NOS2USP2PKM | |
| SCHEMBL27125031 | 0.85 | KDM4E (0.57) | NOS3NOS1NOS2USP2PKM | |
| SCHEMBL9952323 | 0.85 | KDM4E (0.57) | NOS3NOS1NOS2USP2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 493 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119715853-A | Semi-quantitative assessment method for substitution degree of non-protein amino acid | 遵义医科大学 | 2025-03-28 | — | — | CN | claimed |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-28 | — | — | US | claimed |
| CN-116390742-A | Cyclic chemokine-9 derivatives | 拜耳公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4196143-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2023-06-21 | — | — | EP | claimed |
| WO-2022034057-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-17 | — | — | WO | claimed |
| US-8883721-B2 | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof | MCGILL UNIVERSITY (CA) | 2014-11-11 | — | — | US | claimed |
| WO-2013142229-A1 | DESIGNING NOVEL PEPTIDES FOR INDUCING FIBRONECTIN MATRIX ASSEMBLY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-09-26 | — | — | WO | claimed |
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2012-05-31 | — | — | US | claimed |
| WO-2011126882-A2 | THERAPEUTIC PEPTIDES AND THEIR DERIVATIVES AND THERAPEUTIC USES THEREOF | AMERICAN TYPE CULTURE COLLECTION (US) | 2011-10-13 | — | — | WO | claimed |
| WO-2010132580-A2 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2010-11-18 | — | — | WO | claimed |
| US-6906037-B2 | Therapeutic peptide-based constructs | XOMA TECHNOLOGY LTD. (BM) | 2005-06-14 | — | — | US | claimed |
| US-20040048793-A1 | Therapeutic peptide-based constructs | LITTLE ROGER G (US) | 2004-03-11 | — | — | US | claimed |
| US-20030144195-A1 | Therapeutic peptide-based constructs | LITTLE ROGER G (US) | 2003-07-31 | — | — | US | claimed |
| US-6515104-B1 | 8-15 amino acid moieties having heparin neutralization and binding and inhibiting endothelial cell proliferation and/or angiogenesis; diagnotic applications | XOMA TECHNOLOGY LTD. (BM) | 2003-02-04 | — | — | US | claimed |
| US-6423825-B1 | OCTA-, NONA-, DECA- OR POLYPEPTIDE; HEPARIN BINDING AND NEUTRALIZATION; ANTIPROLIFERATIVE AGENTS OF ENDOTHELIAL CELLS; ANGIOGENESIS INHIBITORS | XOMA TECHNOLOGY LTD. (BM) | 2002-07-23 | — | — | US | claimed |
| EP-1196440-A2 | THERAPEUTIC PEPTIDES DERIVED FROM SUBSEQUENCES OF BPI | XOMA Technology Ltd. (US) | 2002-04-17 | — | — | EP | claimed |
| US-6355616-B1 | FUNGICIDE OLIGOPEOTIDES | XOMA (US) TECHNOLOGY LTD. | 2002-03-12 | — | — | US | claimed |
| WO-2001000671-A1 | DERIVATIVE COMPOUNDS | XOMA TECHNOLOGY LTD. (US) | 2001-01-04 | — | — | WO | claimed |
| WO-2001000655-A2 | THERAPEUTIC PEPTIDES DERIVED FROM SUBSEQUENCES OF BPI | XOMA TECHNOLOGY LTD. (US) | 2001-01-04 | — | — | WO | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | GHSR, GIPR, GHRHR | NOS3 638/4885NOS1 880/4885NOS2 1101/4885 |
| US-20030144195-A1 | Therapeutic peptide-based constructs | LNPEP, SPPL2B, ENPEP | NOS3 1714/4885NOS1 1950/4885NOS2 1409/4885 |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | CMKLR1, CMKLR2, CCL2 | NOS3 376/4885NOS1 462/4885NOS2 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.